![](https://wp-static.smartkarma.com/../assets/uploaded/2023/08/Smartkarma-Insight-Card-Square.png)
- Formosa Chemicals’ sales for July 2024 reached NT$30.02 billion.
- July sales showed an increase of 12.2% compared to the previous month.
- Analyst recommendations for Formosa Chemicals include:
- 2 analysts recommend buying the stock.
- 10 analysts advise holding the stock.
- 3 analysts suggest selling the stock.
A look at Formosa Chemicals & Fibre Smart Scores
Factor | Score | Magnitude |
---|---|---|
Value | 5 | |
Dividend | 3 | |
Growth | 2 | |
Resilience | 3 | |
Momentum | 2 | |
OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Formosa Chemicals & Fibre Corporation, a leading manufacturer of petrochemical products, nylon fiber, and rayon staple fiber, appears to have a solid long-term outlook according to Smartkarma Smart Scores. With a high-value score of 5, the company is deemed to be undervalued in the market, presenting a promising investment opportunity. Despite moderate scores in dividend and growth factors, with scores of 3 and 2 respectively, Formosa Chemicals & Fibre demonstrates resilience with a score of 3, indicating its ability to weather economic challenges. However, the company lags behind in momentum with a score of 2, suggesting a slower pace of stock price movement compared to its peers.
Overall, Formosa Chemicals & Fibre‘s Smart Scores paint a picture of a company with strong fundamental value but needing to improve in areas such as growth and momentum to bolster its long-term performance. The company’s focus on manufacturing and marketing petrochemical products, nylon fiber, and rayon staple fiber, with a presence in Taiwan and the broader Asian market, positions it well for potential growth opportunities in the future.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars